Keytruda looks to secure a June double play
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Biomarin hopes long-term valrox data can stem the bleeding
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Reata’s big test approaches
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
Savara hopes to take a leaf out of Insmed’s book
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Krystal gets more skin in the epidermolysis bullosa game
Krystal Biotech shares surged after positive data with its epidermolysis bullosa project, KB103, in just two patients. Now it needs to repeat the trick.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.